312 related articles for article (PubMed ID: 31216704)
1. Inhibitory Antibodies Designed for Matrix Metalloproteinase Modulation.
Fischer T; Riedl R
Molecules; 2019 Jun; 24(12):. PubMed ID: 31216704
[TBL] [Abstract][Full Text] [Related]
2. Design and Structural Evolution of Matrix Metalloproteinase Inhibitors.
Fischer T; Senn N; Riedl R
Chemistry; 2019 Jun; 25(34):7960-7980. PubMed ID: 30720221
[TBL] [Abstract][Full Text] [Related]
3. Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.
Fabre B; Ramos A; de Pascual-Teresa B
J Med Chem; 2014 Dec; 57(24):10205-19. PubMed ID: 25265401
[TBL] [Abstract][Full Text] [Related]
4. Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study.
Singh T; Adekoya OA; Jayaram B
Mol Biosyst; 2015 Apr; 11(4):1041-51. PubMed ID: 25611160
[TBL] [Abstract][Full Text] [Related]
5. Computational Approaches to Matrix Metalloprotease Drug Design.
Singh T; Jayaram B; Adekoya OA
Methods Mol Biol; 2017; 1579():273-285. PubMed ID: 28299743
[TBL] [Abstract][Full Text] [Related]
6. Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.
Arkadash V; Yosef G; Shirian J; Cohen I; Horev Y; Grossman M; Sagi I; Radisky ES; Shifman JM; Papo N
J Biol Chem; 2017 Feb; 292(8):3481-3495. PubMed ID: 28087697
[TBL] [Abstract][Full Text] [Related]
7. Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs.
Jain M; Harburn JJ; Gill JH; Loadman PM; Falconer RA; Mooney CA; Cobb SL; Berry DJ
J Med Chem; 2017 May; 60(10):4496-4502. PubMed ID: 28471664
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
[TBL] [Abstract][Full Text] [Related]
9. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies against metzincin targets.
Santamaria S; de Groot R
Br J Pharmacol; 2019 Jan; 176(1):52-66. PubMed ID: 29488211
[TBL] [Abstract][Full Text] [Related]
11. Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles.
Gimeno A; Beltrán-Debón R; Mulero M; Pujadas G; Garcia-Vallvé S
Drug Discov Today; 2020 Jan; 25(1):38-57. PubMed ID: 31513929
[TBL] [Abstract][Full Text] [Related]
12. Validating the 1,2-Difluoro Motif As a Hybrid Bioisostere of CF
Erdeljac N; Thiehoff C; Jumde RP; Daniliuc CG; Höppner S; Faust A; Hirsch AKH; Gilmour R
J Med Chem; 2020 Jun; 63(11):6225-6237. PubMed ID: 32379447
[TBL] [Abstract][Full Text] [Related]
13. Combined structure- and ligand-based pharmacophore modeling and molecular dynamics simulation studies to identify selective inhibitors of MMP-8.
Kalva S; Vinod D; Saleena LM
J Mol Model; 2014 May; 20(5):2191. PubMed ID: 24756550
[TBL] [Abstract][Full Text] [Related]
14. Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains.
Chen IJ; Chuang CH; Hsieh YC; Lu YC; Lin WW; Huang CC; Cheng TC; Cheng YA; Cheng KW; Wang YT; Chen FM; Cheng TL; Tzou SC
Sci Rep; 2017 Sep; 7(1):11587. PubMed ID: 28912497
[TBL] [Abstract][Full Text] [Related]
15. Identification of Broad-Spectrum MMP Inhibitors by Virtual Screening.
Gimeno A; Cuffaro D; Nuti E; Ojeda-Montes MJ; Beltrán-Debón R; Mulero M; Rossello A; Pujadas G; Garcia-Vallvé S
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361703
[TBL] [Abstract][Full Text] [Related]
16. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
Senn N; Ott M; Lanz J; Riedl R
J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.
Fields GB
Front Immunol; 2019; 10():1278. PubMed ID: 31214203
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Compounds Designed to Inhibit ECM-Modifying Metalloproteinases.
Amar S; Minond D; Fields GB
Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 28613012
[TBL] [Abstract][Full Text] [Related]
19. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.
Rashid ZA; Bardaweel SK
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509
[TBL] [Abstract][Full Text] [Related]
20. Specific interactions between zinc metalloproteinase and its inhibitors: Ab initio fragment molecular orbital calculations.
Ara A; Kadoya R; Ishimura H; Shimamura K; Sylte I; Kurita N
J Mol Graph Model; 2017 Aug; 75():277-286. PubMed ID: 28618335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
